News
In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release ...
Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.
"The Novo Nordisk Foundation is increasing its influence and has appointed its chairman, Lars Rebien Sørensen, as an observer ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results